Abstract 2766
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is an important factor that renders the continuation of chemotherapy difficult. Prevention and treatment of CIPN are indispensable in improving patients’ quality of life and promoting the continuation of chemotherapy that may improve survival. Numbness and pain are currently evaluated using subjective methods such as the visual analogue scale (VAS). However, the assessment of pain can vary greatly depending on the mood and physical state of the patient at the time of assessment. In this stage, objective evaluation methods have not been used for evaluations of CIPN in clinical trials because they have not been established as quantified evaluation methods for CIPN yet. A method to quantify CIPN objectively and easily is necessary. The PainVision PS-2100 (PV) is an analytical instrument that was designed to quantitatively and objectively assess sense perception and nociception in patients. The advantage of PV is that it can evaluate pain in a relatively short time, as well as assess pain without causing further pain to patients.
Methods
We examined a total of 73 CIPN patients with metastatic CRC received chemotherapy between April 2014 and December 2015 by using VAS, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (NTX), the Disk-Criminator™ test, the monofilament test and PV. And then, we evaluated the correlation between subjective and objective evaluation methods or correlation between PV and other objective evaluation methods for CIPN.
Results
The average VAS (hand), VAS (foot) and PV scores of CIPN were 18.4 (range: 0–100), 23.8 (range: 0–100) and 24.7 (range: 0–496), respectively. A strong positive correlation was found between VAS (hand) and VAS (foot) scores (r = 0.798). The VAS (hand), VAS (foot), NTX 2, NTX 4 and NTX 8 significantly correlated with PV. PV showed no correlation with a Disk-Criminator™ or the monofilament test used as an objective evaluation.
Conclusions
This is the 1st report regarding the correlation between PV and other objective evaluation methods in CIPN patients. The evaluation of CIPN is complicated because numerous factors are involved. And further research and effort are needed to improve objective evaluation of CIPN by PV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4242 - HIV, HBV and HCV screening practices in oncology: a cross-sectional interregional survey
Presenter: Isabelle Poizot-Martin
Session: Poster Display session 1
Resources:
Abstract
1267 - Genetic landscape of KEAP1 and NFE2L2 mutated cancers from the AACR GENIE database
Presenter: Mark Zaki
Session: Poster Display session 1
Resources:
Abstract
878 - β-arrestin1 is involved in the Ras-induced malignant transformation
Presenter: Takashi Shibano
Session: Poster Display session 1
Resources:
Abstract
4143 - Incidence of second cancer among PLWHIV: retrospective observational study of a series of 601 patients in the French CANCERVIH network
Presenter: Jean-Philippe Spano
Session: Poster Display session 1
Resources:
Abstract
5145 - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: the CUPISCO trial experience
Presenter: Chantal Pauli
Session: Poster Display session 1
Resources:
Abstract
1737 - Incidence and Outcome of chronic lymphocytic leukemia with Deletion 17p: An Indian experience; challenges and opportunities
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
2596 - Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia
Presenter: Jonathan Killian
Session: Poster Display session 1
Resources:
Abstract
1499 - The potential of a novel antiangiogenic VEGFR1-D2 binding peptide in oncology therapeutics
Presenter: Afsaneh Sadre Momtaz
Session: Poster Display session 1
Resources:
Abstract
1775 - First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Presenter: Mayu Yunokawa
Session: Poster Display session 1
Resources:
Abstract
4584 - First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumors: Dose-optimization cohorts
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract